Project Grant K08CA282966
Award Date
7/30/24
Completion Date
6/30/29
Dollars Obligated
$279K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) provides $695,004 to The University of Texas MD Anderson Cancer Center to conduct research on improving therapies for non-small cell lung cancer patients with HER2-activating mutations. The key objectives are to: 1) Comprehensively characterize the landscape of HER2 mutations associated with response or resistance to HER2-targeted tyrosine kinase inhibitors...
This $449,196 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Texas Southwestern Medical Center to investigate mechanisms of therapeutic resistance in cancer. The research focuses on elucidating how inhibition of receptor tyrosine kinases (RTKs), a common targeted cancer therapy approach, can trigger adaptive responses in cancer cells that lead to secondary resistance. Specifically, the project will...
This Project Grant award from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) provides $256,487 to the Sloan-Kettering Institute for Cancer Research in New York to develop advanced predictive models for non-small cell lung cancer (NSCLC) outcomes. The research aims to improve risk stratification and clinical management of NSCLC by leveraging real-world data from sources like circulating tumor DNA sequencing, radiomics, tumor genomics, and clinical notes....
This $107,948 Project Grant awarded by the National Cancer Institute under CFDA Program 93.398, Cancer Research Manpower, supports research to understand the mechanisms through which the EGFR L858R mutation in lung cancer stimulates an anti-tumor immune response. The principal investigator at Case Western Reserve University will employ advanced genetic and computational tools to:
Fully characterize the EGFR L858R-derived neopeptide and its ability to activate T cells, including determining...
This $450,429 Project Grant award from the National Cancer Institute (NCI), part of the National Institutes of Health, supports research to advance immunotherapy for non-small cell lung cancer (NSCLC) by targeting the MUC1-C protein. The goal is to identify novel therapeutic strategies using anti-MUC1-C antibody-drug conjugates (ADCs) alone and in combination with immune checkpoint inhibitors (ICIs) to enhance anti-tumor immunity and restrain NSCLC progression, particularly for EGFR-mutant...
This federal Project Grant award of $217,863 from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) will support research by the University of Colorado-Denver to study the role of decidual natural killer (DNK) cells and the KIR/HLA axis in melanoma tumor invasion and immune evasion. The two-year project aims to identify biomarkers that can predict risk of disease progression and response to immune checkpoint blockade (ICB) therapy for melanoma patients. The...
The University of Chicago was awarded a $230,010 Project Grant by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to develop innovative methods and tools to investigate the cellular and molecular drivers behind the aggressive metastasis of small cell lung cancer (SCLC). The research strategy will integrate human pluripotent stem cell-derived SCLC models, clinical samples, patient-derived xenografts, and advanced technologies like single-cell sequencing...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development of novel human-relevant lung adenocarcinoma models. The $160,330 award, effective December 1, 2024 through November 30, 2026, aims to:
Introduce oncogenic mutations into primary human lung stem and progenitor cells to generate organoid models for high-throughput drug testing.
Xenograft the mutated stem/progenitor cells into immunodeficient mouse lungs to develop an...
This $127,629 Project Grant, awarded by the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), supports a research project led by Harvard T.H. Chan School of Public Health to elucidate the role of both germline and somatic human leukocyte antigen (HLA) variations in cellular immunity and the efficacy of immune checkpoint inhibitor monotherapy in patients with non-small cell lung cancer. The overarching goal is to leverage multi-omic and clinical data to...
This $700,049 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will fund a 5-year study by the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to examine the impact of tyrosine kinase inhibitor (TKI) cancer treatments on cancer-related cognitive impairment (CRCI) among patients with chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL).
The study aims to characterize differences in objective and subjective CRCI...